Table 4.
Clinical characteristics of kidney transplant recipients stratified by the occurrence of CMV infection.
| Characteristic | CMV Infection | No CMV Infection | p |
|---|---|---|---|
| Age (years) (mean ± SD) | 50.3 ± 13.6 | 46.5 ± 14.6 | 0.143 |
| Gender, male (n [%]) | 30 (60.0) | 60 (68.2) | 0.332 |
| Type of Transplant (n [%]) | |||
| Kidney | 48 (36.1) | 85 (63.9) | 0.371 |
| Kidney + pancreas | 1 (25) | 3 (75) | |
| Kidney + heart | 1 (100) | 0 | |
| Donor (deceased/living) (n [%]) | 49 (38.3)/1(10) | 79 (61.7)/9 (90) | 0.073 |
| Allograft Function (eGFR) (mean ± SD) | |||
| Day 30 | 41.6 ± 16.4 | 49.6 ± 21.1 | 0.040 |
| Day 90 | 40.9 ± 17.1 | 51.6 ± 18.2 | 0.0006 |
| Acute Rejection (n [%]) | |||
| TCMR | 18 (42.9) | 24 (57.1) | 0.639 |
| ABMR | 8 (47.1) | 9 (52.9) | 0.521 |
| TCMR or ABMR | 22 (44.9) | 27 (55.1) | 0.362 |
| HLA Mismatch (n [%]) | |||
| ≤3/6 | 25 (40.3) | 37 (59.7) | 0.366 |
| >3/6 | 25 (32.9) | 51 (67.1) | |
| Lymphocyte blood count ≤ day 90 (G/L) (n [%]) | |||
| <0.8 | 31 (56.4) | 24 (43.6) | 0.0003 |
| ≥0.8 | 17 (24.6) | 52 (75.4) | |
| Leukocyte Blood Count ≤ Day 90 (G/L) (n [%]) | |||
| <4.1 | 34 (46.6) | 39 (53.4) | 0.007 |
| ≥4.1 | 16 (24.6) | 49 (75.4) | |
| Donor (n [%]) | |||
| CMV IgG+ | 45 (37.5) | 75 (62.5) | 0.752 |
| CMV IgG− | 5 (33.3) | 10 (66.7) | |
| Pretransplant Recipient CMV Serostatus (n [%]) | |||
| CMV IgG+ | 32 (31.7) | 69 (68.3) | 0.066 |
| CMV IgG− | 18 (48.7) | 19 (51.3) | |
| Pretransplant recipient CMV IgG titer day 0 (AU/mL) (mean ± SD) | 80.7 (95.9) | 133.4 (116.6) | 0.016 |
| Pretransplant Donor/Recipient CMV Serostatus (n [%]) | |||
| D+/R− | 18 (52.9) | 16 (47.1) | 0.019 |
| D+ or D−/R+ | 32 (30.8) | 72 (69.2) | |
| Duration of antiviral prophylaxis (days) (mean ± SD) | 80 ± 23 | 87 ± 19 | 0.276 |
| Time from kidney transplant to antiviral prophylaxis initiation (days) (mean ± SD) | 4.68 ± 4.97 | 7.22 ± 5.39 | 0.005 |
| Induction Therapy (%) | |||
| Yes (basiliximab) | 27.8 | 72.2 | 0.076 |
| Yes (thymoglobulin) | 53.8 | 46.2 | |
| No | 43.4 | 56.6 | |
| Induction Therapy (%) | |||
| Yes (basiliximab or thymoglobulin) | 31.8 | 68.2 | 0.166 |
| No | 43.4 | 56.6 | |
eGFR, estimated glomerular filtration rate; TCMR, T-cell mediated rejection; ABMR, antibody-mediated rejection; HLA, human leukocyte antigen; SD, standard deviation; AU, arbitrary units.